Capitalizing on my two great talents, op-eds and bad puns, I've created a section on my website called Op-Education. The point, you might have already guessed, is to give people guidance on how to write a smart commentary piece. https://t.co/885Wrlsmn0
Our review of a challenging disease with @zde_p @DrCraigSauter and others: Current Treatment of Peripheral T-cell Lymphoma https://t.co/6hKOtjD0Wd via @CancerNetwrk
Reinstalled the Twitter app and breaking my silence to highly recommend this episode. If you’ve dealt with #impostersyndrome (irrespective of your profession/field) like I have and continue to, I think you’ll find this conversation really worthwhile. https://t.co/0xUtREKAeB
2020 was a rough year for many people. Towards the end of the year, it was the time that I was diagnosed with an acoustic neuroma and subsequently underwent surgery. 🧵 https://t.co/xBjozRCwOm
While this is wonderful, it is news primarily because something as simple as stating and defending scientific principles will likely result in death threats for Francis Collins, all because one of the two major political parties is committed to demonizing empiricism.
The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma #lymphoma#lymsm https://t.co/UD3ieEeUzq
Working with #valentinanardi and #david_weinstock, @ktlee201 found recurrent jak2 fusions in aggressive skin lymphomas. her work has launched a clinical trial at NU and MSKCC! Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterat... https://t.co/hcSU7POJci
Models of inter-patient heterogeneity can predict clinical efficacy of drug combinations for advanced incurable cancers, but curative therapy is more complex. We now have models of intra- and inter-tumor heterogeneity, and they match the first success in 20 yrs for 1st line DLBCL
Our perspective on EZH2 biology and therapeutic targeting @DrStephenAnsell @MayoClinic @MayoHemeOnc Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma: Expert Opinion on Pharmacotherapy: Vol 0, No 0 https://t.co/LclzCEAQMT
LATER at 6:00PM EST: LRF grantee Elizabeth Brem, MD of @UCIrvineHealth to present findings from phase III study of R-miniCHOP w/ oral Azacitidine (CC-486) to treat various B-cell #lymphomas in patients newly diagnosed age 75 or older. #ASH21
Read more: https://t.co/FEmbRU9zZa
We have a fully funded postdoctoral fellow position available. The candidate will investigate molecular drivers of T cell lymphomas using clinically relevant mouse models and patient sample correlatives from clinical trials! https://t.co/3YcFo189ro